Literature DB >> 3174751

The comparative binding characteristics of nicotinic ligands and their pharmacology.

J W Sloan1, W R Martin, M Bostwick, R Hook, E Wala.   

Abstract

Five drugs [(-)- and (+)-nicotine, (-)-lobeline, (-)-anabasine and (-)-cytisine] were infused IV into the urethane-pentobarbital anesthetized rat. Changes in heart rate, blood pressure, respiratory rate, minute and tidal volume, which appeared to be largely centrally mediated, were studied. Each of these compounds produced different pharmacologic profiles. The nature of these dissimilarities is not readily explained on the basis of pharmacokinetic considerations suggesting that the drugs have different mechanisms of action. Binding data obtained with these compounds using the rat brain P2 preparation also show differences. (-)-Lobeline and (-)-anabasine, like the nicotinic antagonists mecamylamine and hexamethonium, bind predominantly to low affinity sites with KDs in the micromolar range whereas (-)-cytisine binds only to a single high affinity site with a KD in the nanomolar range. Further, the binding patterns of these drugs are different from (-)- and (+)-nicotine which bind to both high and low affinity sites but differ from each other in binding characteristics. Thus the binding data are consistent with the pharmacologic data in suggesting that the drugs have different modes of action and support the concept that the low affinity site has an important role in the central nervous system action of these compounds.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3174751     DOI: 10.1016/0091-3057(88)90454-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

1.  Patterns of nicotinic receptor antagonism: nicotine discrimination studies.

Authors:  Emily M Jutkiewicz; Emily A Brooks; Adam D Kynaston; Kenner C Rice; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2011-07-05       Impact factor: 4.030

2.  Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5.

Authors:  Imju Jeong; Bok Hee Choi; Sang June Hahn
Journal:  Pflugers Arch       Date:  2010-08-24       Impact factor: 3.657

Review 3.  Nicotiana glauca (tree tobacco) intoxication--two cases in one family.

Authors:  Victoria Furer; Moshe Hersch; Noa Silvetzki; Gabriel S Breuer; Shoshana Zevin
Journal:  J Med Toxicol       Date:  2011-03

4.  An uncontrolled trial of cytisine (Tabex) for smoking cessation.

Authors:  Witold Zatonski; Magdalena Cedzynska; Piotr Tutka; Robert West
Journal:  Tob Control       Date:  2006-12       Impact factor: 7.552

5.  Discriminative stimulus properties of the nicotinic agonist cytisine.

Authors:  C J Chandler; I P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

Review 6.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

7.  Patterns of nicotinic receptor antagonism II: cardiovascular effects in rats.

Authors:  Emily M Jutkiewicz; Kenner C Rice; F Ivy Carroll; James H Woods
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

8.  In vivo effects of 3-iodocytisine: pharmacological and genetic analysis of hypothermia and evaluation of chronic treatment on nicotinic binding sites.

Authors:  C A Zambrano; M J Marks; B K Cassels; R B Maccioni
Journal:  Neuropharmacology       Date:  2009-05-28       Impact factor: 5.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.